期刊文献+

高血压患者血清脂联素水平和动脉顺应性的关系 被引量:3

Serum Adiponectin and Arterial Compliance in Patients of Hypertension
下载PDF
导出
摘要 目的探讨高血压人群中血清脂联素浓度和动脉顺应性之间的关系。方法入选非糖尿病的高血压受试者83例,分为药物治疗组和未治疗组。常规检测受试者的坐位血压及部分血清生化指标,包括血糖、血脂、肝功能、肾功能和胰岛素水平;放射免疫法检测血清脂联素浓度;计算稳态模式胰岛素抵抗指数(HOMA-IR);用HDICVprofilor DO-2020检测大动脉弹性指数(C1)和小动脉弹性指数(C2)。结果比较药物治疗组和未治疗组,发现前者的脂联素浓度(中位数:11.9μg/mL)、C1(中位数:13.7mL/mmHg×10)、C2(中位数:4.3mL/mmHg×100)均明显高于后者(5.7μg/mL,10.7mL/mmHg×10,3.7mL/mmHg×100,P均<0.01)。对未治疗组进行相关分析发现LogC1与脂联素浓度明显正相关(r=0.54,P<0.01),与平均血压(MBP)负相关(r=-0.40,P<0.05);LogC2和脂联素浓度明显正相关(r=0.49,P<0.01),与HOMA-IR和MBP明显负相关(LogC2-HOMA-IRr=-0.40,P<0.05;LogC2-MBP,r=-0.32,P<0.01);另外还发现C1与心率(HR)负相关(LogC1-HRr=-0.41,P<0.01)。多元线性逐步回归分析发现血清脂联素浓度和HR水平以及性别是LogC1的独立影响因素(R2=0.39,P<0.01);血清脂联素水平和性别是LogC2的独立影响因素(R2=0.44,P<0.01)。结论高血压人群中C1,C2的减退与血清脂联素浓度的降低密切相关。接受抗高血压药物治疗的患者,血清脂联素浓度和动脉顺应性水平升高。 Objective To investigate the relation between serum adiponectin and arterial compliance in patients with hypertension. Methods Eighty three hypertensives without diabetes were enrolled into medication treatment group and none-medication treatment group. Serum adiponectin was detected by radioimmunology assay and arterial compliance was determined by the device of HDI CVprofilorDO-2020. Insulin resistant index was defined as HOMA-IR. Results Medication treatment group had a higher concentration of serum adiponectin and level of C1, C2( P〈0.01). In the untreatment group, LogC1 was correlated with adiponectin(r=0.54, P〈 0. 01), HR (r=-0.41, P〈0. 05) and MBP (r=-0. 40, P〈0.05); LogC2 was correlated with adiponectin(r= 0. 49, P〈0. 01 ), HOMA-IR (r=-0.40, P〈0.05). Multivariate linear regression analysis showed that serum adiponectin, HR and gender were independent predictors for large arterial compliance(R2 =0.39, P〈0.01) ; adiponectin in serum and gender were independent predictors for small arterial compliance(R2 = 0.44, P〈0. 01 ). Conclusion Serum adiponectin was closely related with arterial stiffness(C1 , C2 ) in subjects with hypertension. Medication treatment for hypertensives increase serum adiponectin and level of C1 , C2.
出处 《中华高血压杂志》 CAS CSCD 北大核心 2007年第6期489-492,共4页 Chinese Journal of Hypertension
关键词 高血压 脂联素 动脉顺应性 Hypertension Adiponectin Arterial compliance
  • 相关文献

参考文献10

  • 1何华美,汪海,肖文彬.血管内皮细胞功能失调与高血压[J].国外医学(药学分册),1999,26(2):79-84. 被引量:25
  • 2[2]Ouchi N,Kihara S,Arita Y,et al.Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin[J].Circulation,1999,100:2473-2476.
  • 3[3]Adamczak M,Wiecek A,Funahashi T,et al.Decreased plasma adiponectin concentration in patients with essential hypertension[J].Am J Hypertens,2003,16:72-75.
  • 4李丙蓉,邓华聪.脂联素、球状脂联蛋白与糖尿病动脉粥样硬化[J].中国动脉硬化杂志,2005,13(6):799-802. 被引量:5
  • 5[7]Mahmud A,Feely J.Adiponectin and arterial stiffness[J].Am J Hypertens,2005,18(12 Pt 1):1543-1548.
  • 6[8]Matsuda M,Shimomura I,Sata M,et al.Role of adiponectin in preventing vascular stenosis.The missing link of adipo-vascular axis[J].J Biol Chem,2002,277:37487-37491.
  • 7[9]Furuhashi M,Ura N,Higashiura K,et al.Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension[J].Hypertens,2003,42:76-81.
  • 8[10]Tsatsanis C,Zacharioudaki V,Androulidaki A,et al.Adiponectin induces TNF-α and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli[J].Biochem Biophys Res Commun,2005,335:1254-1263.
  • 9[11]Berg AH,Scherer PE.Adipose tissue,inflammation,and cardiovascular disease[J].Circ Res,2005,96:939-949.
  • 10李嘉强,戴颖秀,刘玉敏,郑基,刘文斌.高血压患者血清脂联素与游离脂肪酸、糖及脂代谢[J].高血压杂志,2006,14(5):352-355. 被引量:24

二级参考文献6

共引文献51

同被引文献31

  • 1郑洁,黄家金,郑咏梅,韦玲,邓小莲.广东省壮族地区高血压流行病学调查[J].中国热带医学,2006,6(6):1099-1100. 被引量:3
  • 2李为民,刘巍.2005年中国高血压防治指南评介[J].中国实用内科杂志,2007,27(12):899-902. 被引量:73
  • 3唐敏,程开诚,王光富,宫育恒,苏海.卡托普利与缓释硝苯地平对高血压患者血清瘦素的影响[J].中华高血压杂志,2007,15(7):579-582. 被引量:5
  • 4Ohashi K, Kihara S, Ouchi N, et al. Adiponeetin replenishment ameliorates obesity-related hypertension [J]. Hypertension, 2006,47(6):1108-1116.
  • 5Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion [J]. Arch Intern Med,2008, 168(11): 1159- 1164.
  • 6Reynolds RM, Walker BR, Phillips DI, et al. Programming of hypertension:associations of plasma aldosterone in adult men and women with birthweight, cortisol, and blood pressure[J]. Hypertension, 2009,53(6) :932-936.
  • 7Krug AW, Ehrhart-Bornstein M. Aldosterone and Metabolic Syndrome: Is increased aldosterone in metabolic syndrome patients an additional risk factor? [J].Hypertension, 2008,51 (5):1252-1258.
  • 8Tao L, Gao E, Jiao X, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress [J]. Circulation, 2007,115 ( 11 ) : 1408- 1416.
  • 9von Eynatten M, Schneider JG, Humpert PM, et al. Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men[J].J Am Coll Cardiol,2006,47 (10):2124-2126.
  • 10Cheng KK, Lain KS, Wang Y, et al. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells[J]. Diabetes,2007,56(5): 1387-1394.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部